May 26, 2026 —
Researchers at the University of California, San Diego have reported preclinical data supporting a new gene therapy strategy for TDP-43–associated neurodegeneration, a disease mechanism increasingly linked to frontotemporal dementia, amyotrophic lateral sclerosis, and a large proportion of Alzheimer’s disease cases.
The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, evaluated systemic delivery of SynCav1, a gene therapy designed to increase expression of caveolin-1, a scaffolding protein involved in membrane signaling, synaptic function, and neuronal resilience. Rather than directly removing toxic TDP-43, the approach aims to strengthen neurons’ ability to withstand TDP-43–driven stress and degeneration.
TDP-43 pathology is associated with protein misfolding, abnormal cellular localization, cognitive decline, brain atrophy, memory loss, and neuronal dysfunction. In the UCSD study, researchers packaged SynCav1 into a modified AAV vector capable of crossing the blood-brain barrier, enabling broad delivery to the brain and spinal cord after systemic administration. This is notable because many CNS-directed gene therapies require direct injection into the brain or cerebrospinal fluid.
In TDP-43A315T mouse models, SynCav1 preserved learning and memory function and reduced pathological TDP-43 levels in the cortex and hippocampus. The therapy also protected neuronal structure at multiple levels, including mitochondrial integrity, membrane lipid raft organization, synaptic signaling, axonal myelin structure, and GluN2A receptor expression, which is important for excitatory synaptic function.
Mechanistically, the researchers observed that pathological TDP-43 mislocalized to membrane lipid rafts, disrupting key signaling domains required for neuronal communication. SynCav1 appeared to preserve these membrane signaling structures and support healthier subcellular organization. Electron microscopy further showed that SynCav1 reduced mitochondrial hyper-fragmentation and excessive fission signaling, suggesting broader protection against cellular stress.
Although the findings remain preclinical, the study highlights an important therapeutic concept: neurodegenerative disease treatment may not need to rely only on removing toxic proteins. Strengthening neuronal resilience and preserving cellular architecture may offer a complementary strategy, especially in complex diseases where TDP-43 pathology contributes to cognitive decline and neurodegeneration.
If successfully translated, SynCav1 could represent a neuron-centered AAV gene therapy approach with potential relevance across multiple TDP-43–linked disorders, including FTD, ALS, and Alzheimer’s disease.
